Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06514547 · ClinicalTrials.gov registry record · Phase 4
Vaccine Immunity and Inflammation in the Aging Person Living With HIV
A Phase 4 study of HIV Infections and Age, sponsored by Hennepin Healthcare Research Institute.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 250
- Enrollment target
- 1
- Study location
NCT06514547 is a Phase 4 study of HIV Infections and Age that is actively recruiting participants, run by Hennepin Healthcare Research Institute. The registered enrollment target is 250 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (44% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06514547, a Phase 4 study of HIV Infections and Age, is actively recruiting participants, sponsored by Hennepin Healthcare Research Institute.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 250 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will track immune responsiveness to conjugate pneumococcal vaccines over time to help determine how long protection from this vaccine lasts in individuals with chronic medical conditions (in this study - HIV) and with age.
Conditions Studied
Interventions
- BIOLOGICAL Conjugate Pneumococcal Vaccine 20 (PCV20)
Study Locations (1)
Minnesota
- Hennepin Healthcare System - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2024-07-08 |
| Est. Completion | 2029-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06514547
The ClinicalTrials.gov registry entry for NCT06514547 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (44% lower). The listed sponsor is Hennepin Healthcare Research Institute, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Conjugate Pneumococcal Vaccine 20 (PCV20) is the first listed.
NCT06514547 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT06514547 about?
NCT06514547 is a clinical study titled "Vaccine Immunity and Inflammation in the Aging Person Living With HIV". This study will track immune responsiveness to conjugate pneumococcal vaccines over time to help determine how long protection from this vaccine lasts in individuals with chronic medical conditions (in this study - HIV) and with age.
What is the current status of trial NCT06514547?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 250 participants. The study started on 2024-07-08. Estimated completion is 2029-06-30.
What conditions does trial NCT06514547 study?
This clinical trial studies the following conditions: HIV Infections, Age.
What interventions are being tested in trial NCT06514547?
The interventions under investigation include: Conjugate Pneumococcal Vaccine 20 (PCV20) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06514547?
This trial is sponsored by Hennepin Healthcare Research Institute, which has 63 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06514547 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Accelerated ART Initiation for PWHIV Who Are Out of Care
RECRUITING · Phase 4
-
PrEP Intervention for People Who Inject Substances and Use Methamphetamine
RECRUITING · Phase 4
-
Boosted Atazanavir and Truvada Given Once-Daily - BATON Study
COMPLETED · Phase 4
-
"The Once A Day Protease Inhibitor Regimens"
COMPLETED · Phase 4
-
Buprenorphine and Integrated HIV Care
COMPLETED · Phase 4
-
Gradual Initiation of Sulfamethoxazole/Trimethoprim as Primary Pneumocystis Carinii Pneumonia Prophylaxis
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.